242 related articles for article (PubMed ID: 28514755)
1. A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT).
Wang X; Zhi X; Yang Z; Tian H; Li Y; Li M; Zhao W; Zhang C; Wang T; Liu J; Shen D; Zheng C; Zhao D; Yang S; Qi J; Xin H; Stojadinovic A; Avital I; Lee LJ; Rao J; Zhang W
Oncotarget; 2017 Jul; 8(28):45345-45355. PubMed ID: 28514755
[TBL] [Abstract][Full Text] [Related]
2. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
3. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
4. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
[TBL] [Abstract][Full Text] [Related]
5. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
6. Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
Triphuridet N; Vidhyarkorn S; Worakitsitisatorn A; Sricharunrat T; Teerayathanakul N; Auewarakul C; Chungklay N; Krongthong W; Luengingkasoot S; Sornsamdang G; Patumanond J; Sritipsukho P
Lung Cancer; 2018 Aug; 122():243-248. PubMed ID: 30032839
[TBL] [Abstract][Full Text] [Related]
7. Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer.
Wang X; Yang Z; Tian H; Li Y; Li M; Zhao W; Zhang C; Wang T; Liu J; Zhang A; Shen D; Zheng C; Qi J; Zhao D; Shi J; Jin L; Rao J; Zhang W
Oncotarget; 2017 Apr; 8(15):24892-24901. PubMed ID: 28206963
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
; Guida F; Sun N; Bantis LE; Muller DC; Li P; Taguchi A; Dhillon D; Kundnani DL; Patel NJ; Yan Q; Byrnes G; Moons KGM; Tjønneland A; Panico S; Agnoli C; Vineis P; Palli D; Bueno-de-Mesquita B; Peeters PH; Agudo A; Huerta JM; Dorronsoro M; Barranco MR; Ardanaz E; Travis RC; Byrne KS; Boeing H; Steffen A; Kaaks R; Hüsing A; Trichopoulou A; Lagiou P; La Vecchia C; Severi G; Boutron-Ruault MC; Sandanger TM; Weiderpass E; Nøst TH; Tsilidis K; Riboli E; Grankvist K; Johansson M; Goodman GE; Feng Z; Brennan P; Johansson M; Hanash SM
JAMA Oncol; 2018 Oct; 4(10):e182078. PubMed ID: 30003238
[TBL] [Abstract][Full Text] [Related]
9. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
10. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer.
Chen X; Wang X; He H; Liu Z; Hu JF; Li W
PLoS One; 2015; 10(5):e0126276. PubMed ID: 25996878
[TBL] [Abstract][Full Text] [Related]
11. Multiplexed Serum Biomarkers for the Detection of Lung Cancer.
Ma S; Wang W; Xia B; Zhang S; Yuan H; Jiang H; Meng W; Zheng X; Wang X
EBioMedicine; 2016 Sep; 11():210-218. PubMed ID: 27575387
[TBL] [Abstract][Full Text] [Related]
12. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.
Sestini S; Boeri M; Marchiano A; Pelosi G; Galeone C; Verri C; Suatoni P; Sverzellati N; La Vecchia C; Sozzi G; Pastorino U
Oncotarget; 2015 Oct; 6(32):32868-77. PubMed ID: 26451608
[TBL] [Abstract][Full Text] [Related]
13. [Macrophage Inhibitory Cytokine-1 (MIC-1) as A Biomarker for Diagnosis
and Prognosis of Stage I-II Non-small Cell Lung Cancer].
Liu Y; Wang X; Wang T; Zhang C; Zhang K; Zang R; Zhi X; Zhang W; Sun K
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):207-15. PubMed ID: 27118648
[TBL] [Abstract][Full Text] [Related]
14. Combination of IL-6, IL-10, and MCP-1 with traditional serum tumor markers in lung cancer diagnosis and prognosis.
Pan YW; Zhou ZG; Wang M; Dong JQ; Du KP; Li S; Liu YL; Lv PJ; Gao JB
Genet Mol Res; 2016 Nov; 15(4):. PubMed ID: 27819723
[TBL] [Abstract][Full Text] [Related]
15. Combined detection of CEA and CA125 for the diagnosis for lung cancer: A meta-analysis.
Wu LX; Li XF; Chen HF; Zhu YC; Wang WX; Xu CW; Xie DF; Wan Y; Du KQ
Cell Mol Biol (Noisy-le-grand); 2018 Dec; 64(15):67-70. PubMed ID: 30672447
[TBL] [Abstract][Full Text] [Related]
16. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
17. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory.
Hui L; Rixv L; Xiuying Z
Clin Biochem; 2015 Dec; 48(18):1241-5. PubMed ID: 26216289
[TBL] [Abstract][Full Text] [Related]
18. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
[TBL] [Abstract][Full Text] [Related]
19. Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study.
Yang D; Zhang X; Powell CA; Ni J; Wang B; Zhang J; Zhang Y; Wang L; Xu Z; Zhang L; Wu G; Song Y; Tian W; Hu JA; Zhang Y; Hu J; Hong Q; Song Y; Zhou J; Bai C
Cancer; 2018 Jan; 124(2):262-270. PubMed ID: 28940455
[TBL] [Abstract][Full Text] [Related]
20. Multimodal lung cancer screening using the ITALUNG biomarker panel and low dose computed tomography. Results of the ITALUNG biomarker study.
Carozzi FM; Bisanzi S; Carrozzi L; Falaschi F; Lopes Pegna A; Mascalchi M; Picozzi G; Peluso M; Sani C; Greco L; Ocello C; Paci E;
Int J Cancer; 2017 Jul; 141(1):94-101. PubMed ID: 28387927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
